Janux Therapeutics JANX Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's return on invested capital?
- Janux Therapeutics (JANX) reported return on invested capital of -16.8% in Q1 2026.
- How has Janux Therapeutics's return on invested capital changed year-over-year?
- Janux Therapeutics's return on invested capital decreased by 5.4% year-over-year, from -15.9% to -16.8%.
- What is the long-term trend for Janux Therapeutics's return on invested capital?
- Over 3 years (2022 to 2025), Janux Therapeutics's return on invested capital has grown at a -1.6% compound annual growth rate (CAGR), from -21.5% to -20.5%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.